A two-year randomized controlled trial in Shanghai found that stronger atropine eye drops meaningfully slowed severe myopia progression in children with high myopia. The study evaluated nightly dosing and reported a significant difference versus weaker concentrations. The result adds clinical support for dose-intensification strategies in pediatric myopia control, a space where adherence and long-term efficacy remain central practical challenges. For biotech and medtech stakeholders, the update reinforces demand for differentiated optical pharmacology and longer-duration data in myopia management programs.